A Swedish company using AI to speed up cancer diagnoses has opened its first UK laboratory in Oxfordshire.
Inify Laboratories has moved into Milton Park’s Nebula development, where a custom-built, AI-enabled laboratory will help it to meet the UK’s rising demand for cancer diagnostics.
Kate Bucknall, managing director of Inify UK, said: "Our new base at Milton Park is a real milestone in our mission to improving cancer care and reducing delays in patient pathways.
"Our recent success shows that digitised, AI-supported workflows can halve the time from biopsy to diagnosis, which has been transformative for both patients and clinicians in Sweden."
The company currently processes around 80 per cent of Stockholm’s prostate biopsies and 10 per cent of Sweden’s total.
In Sweden, Inify delivers results in five working days or less, averaging just 3.5 days.
In comparison, NHS patients in the UK typically wait two to three weeks for their results.
Inify’s AI software, INIFY Prostate, has been clinically proven to deliver more than 99 per cent sensitivity and 97 per cent specificity.
Every case is reviewed by a specialist pathologist before a final report is issued.
The new laboratory at Nebula will combine Inify’s clinical, laboratory, and commercial operations under one roof.
The facility is designed to manage the entire diagnostic process, including sample logistics, tissue processing, digitisation, AI analysis, and expert review.
Ms Bucknall said: “With around 120,000 prostate biopsy patients requiring support every year, the UK’s demand for diagnostics is around six times larger than in Sweden.
"In the UK, our ageing population, growing awareness, and a national shortage of pathologists and biomedical scientists mean we have a significant bottleneck in prostate diagnosis.
"We want to tackle that challenge head-on in our new facility, by giving patients answers as soon as possible, while providing quality and efficiency gains across the pathway.
“After an extensive search, we chose Milton Park based on its vibrant community, strong transport links, and access to exceptional talent near Oxford and London.
"The Inify lab will have capacity to handle a volume similar to the country’s total demand.
Tom Booker, commercial manager at Milton Park, added: "We’re thrilled that Inify has chosen Milton Park as its UK home.
"The team’s decision to join the Milton Park community reinforces our position as a home for leading life science and med-tech organisations to collaborate, innovate, and grow.
"Inify’s work in Sweden is a real example of how innovation can deliver meaningful impact in healthcare.
"We look forward to seeing the difference it can make on patient outcomes in its new UK base here at Milton Park."
